Lilly Contract Sales Team Will Hit The Diabetes Market “Within Weeks”
This article was originally published in The Pink Sheet Daily
The contract team will also be cross-trained on other Lilly products.
You may also be interested in...
Competition from Merck's DPP-4 inhibitor Januvia and progress made by Lilly's own Byetta alter firm's insulin market expectations.
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.
Novo Nordisk tells “The Pink Sheet” DAILY it has started recruiting reps; it intends to add 700 next year.